摘要
神经母细胞瘤(neuroblastoma,NB)起源于神经嵴,是儿童和婴儿最常见的颅外实体肿瘤。NB在组织分布、临床特征和病理分子生物学上有较大差异,部分低危NB患儿5年生存率约95%,但高危NB患儿生存率仅40%~50%。因此,对于复发和难治的NB治疗仍面临巨大挑战。随着分子生物学进步,对NB的病理分子生物学特点认识进一步提高,出现了许多NB治疗方法和预后标志物,特别是许多用于治疗高危和复发、难治的NB靶向药物。本文对NB的分子生物学特点和靶向药物的临床治疗进行综述。
Neuroblastoma is the most common extracranial solid tumor in childhood originating from the neural crest.Neuroblastomas are heterogeneous in terms of location,histopathologic appearance,biological characteristics,and clinical presentations.For patients in the low-risk group,the 5-year survival rate is higher than 95%;however,the 5-year survival rate is approximately 40%-50%for patients in the high-risk group.Patients with refractory or relapsed high-risk neuroblastoma continue to experience poor outcomes.Based on advancements in understanding the pathological and molecular characteristics of neuroblastoma,many new targeted therapies and prognostic biomarkers have been applied in neuroblastoma treatment.This review focused on recent advances in the molecular biology of neuroblastoma and targeted therapies that have emerged in clinical trials.
作者
左彤彤
周卫萍(综述)
郑洁虹(审校)
Tongtong Zuo;Weiping Zhou;Jiehong Zheng(Department of Pediatric Neurosurgery,Xin Hua Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200092,China;Department of Adult Neurosurgery,Xin Hua Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200092,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2021年第8期426-431,共6页
Chinese Journal of Clinical Oncology
